John Turman Fleming Sells 2,450 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director owned 4,230 shares of the company’s stock, valued at $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

USANA Health Sciences Stock Down 1.3%

USNA stock opened at $18.09 on Wednesday. The stock has a market capitalization of $333.94 million, a P/E ratio of 38.49, a P/E/G ratio of 0.72 and a beta of 0.76. The firm has a 50-day simple moving average of $18.33 and a 200-day simple moving average of $19.46. USANA Health Sciences, Inc. has a 52 week low of $16.60 and a 52 week high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The firm had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, analysts expect that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. National Bank of Canada FI increased its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares during the last quarter. State of Wyoming acquired a new position in USANA Health Sciences during the first quarter worth $57,000. Tower Research Capital LLC TRC boosted its stake in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after buying an additional 1,901 shares during the last quarter. Parallel Advisors LLC grew its holdings in USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after buying an additional 3,589 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after buying an additional 1,327 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on USNA shares. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Finally, Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.